THE QUALITY OF WELL-BEING SCALE - APPLICATIONS IN AIDS, CYSTIC-FIBROSIS, AND ARTHRITIS
THE QUALITY OF WELL-BEING SCALE - APPLICATIONS IN AIDS, CYSTIC-FIBROSIS, AND ARTHRITIS
复制标题
DOI：
10.1097/00005650-198903001-00003
复制
发表时间：
1989-03-01
期刊：
影响因子：
3
通讯作者：
ORENSTEIN, D
中科院分区：
文献类型：
--
作者：
KAPLAN, RM;ANDERSON, JP;ORENSTEIN, D
幸福质量（QWB）量表结合了症状和功能的偏好加权测量，以提供幸福的数值时间点表达，范围从死亡的零（0）到无症状的最佳功能的1.0。QWB包括三个功能量表：移动性，身体活动和社会活动。这些尺度的每一步都与偏好权重相关联。还包括对症状的偏好调整。本文描述了如何使用这个通用系统来评估三种不同临床条件下的结果：获得性免疫缺陷综合征（AIDS），囊性纤维化和关节炎。在一项研究中，QWB被给予31名患者参与评价叠氮胸苷（AZT）治疗艾滋病。QWB系统证明了与安慰剂相比，AZT治疗的实质性益处。在第二项研究中，对44名囊性纤维化患者进行了QWB和一系列肺功能测量。QWB与肺功能指标FEV1和最大呼气中段流速（MMEFR）显著相关。此外，QWB和运动耐量测量之间存在显著关联。在第三项研究中，QWB和关节炎特异性措施在治疗前后给予83名关节炎患者。QWB至少能够像疾病特异性测量一样检测该人群的临床变化。对于所有这三种情况，QWB考虑了共同单位治疗的副作用和益处。引用临床试验数据表明，QWB是关节炎治疗评价中有价值的结局指标。我们的结论是，QWB作为一个一般的健康结果的措施，该系统可以用于不同的人群有很大的有效性。
The Quality of Well-being (QWB) Scale combines preference-weighted measures of symptoms and functioning to provide a numerical point in-time expression of well-being that ranges from zero (0) for death to 1.0 for asymptomatic optimum functioning. The QWB includes three scales of function: mobility, physical activity, and social activity. Each step of these scales is associated with preference weights. Preference adjustments for symptoms are also included. This paper describes how this general system was used to evaluate outcomes in three different clinical conditions: acquired immune deficiency syndrome (AIDS), cystic fibrosis, and arthritis. In one study, the QWB was administered to 31 patients participating in evaluation of azidothymidine (AZT) treatment for AIDS. The QWB system demonstrated substantial benefits of AZT treatment in comparison to placebo. In a second study, the QWB and a series of pulmonary function measures were administered to 44 patients with cystic fibrosis. The QWB was demonstrated to be significantly correlated with measures of pulmonary function, including FEV 1 and maximal midexpiratory flow rate (MMEFR). In addition, there were significant associations between the QWB and measures of exercise tolerance. In the third study, the QWB and an arthritis-specific measure were administered to 83 arthritis patients before and after their treatment. The QWB was at least as capable of detecting clinical change in this population as was the disease-specific measure. For all three conditions, the QWB considered side effects and benefits of treatment in a common unit. Clinical trial data are cited to suggest that the QWB is a valuable outcome measure in arthritis treatment evaluation. We conclude that the QWB has substantial validity as a general health outcome measure and that the system can be used with different populations.